摘要
目的探讨尼妥珠单抗与同步放化疗联合治疗局部晚期头颈部恶性肿瘤的近期疗效和不良反应。方法以根治性同步放化疗同时给予尼妥珠单抗治疗作为试验组(32例),以根治性同步放化疗作为对照组(30例)。两组基线情况,性别、年龄、肿瘤部位、肿瘤分期、生化指标、血常规指标等具有可比性。根治性放射治疗总剂量66～72Gy,尼妥珠单抗治疗,剂量为100～200mg/次,静脉滴注,每周给药1次,连用6周。结果试验组原发灶、淋巴结的完全缓解率(CR)分别为65.62%,68.75%,均优于对照组,差异有统计学意义(P<0.05)。试验组和对照组不良反应发生率之间无明显差异(P>0.05)。结论尼妥珠单抗联合放疗可能提高局部晚期头颈部恶性肿瘤的近期疗效,药物不良反应轻微,对治疗局部晚期头颈部恶性肿瘤可能有临床应用价值。
Objective To evaluate the side-effect and outcome of nimotuzumab combined with current chemoradiotherapy for advanced stage head and neck tumor.Methods The intervention measures in treatment group（n=32） were current chemoradiotherapy combined with nimotuzumab.The intervention measures in control group（n=30） were current chemoradiotherapy.There were no statistical differences in two group′s baseline information,including sex,age,tumor position,staging,biochemical indicator,blood indicator（P0.05）.The radiotherapy accumulated dose were 66~72 Gy,the nimotuzumab therapeutics dose was 200 mg/time,intravenous drip,1 time per week,continuous for 6 weeks.Results The curative effect of treatment group surpassed to control group,the remission rate for primarily focus was 65.62%（χ2=10.854,P=0.001）,the remission rate for lymph follicle was 68.75%（χ2=4.249,P=0.039）.There were no statistical differences of two group＇s incidence rate for side-effect（P0.05）.Conclusion This study demonstrated that the use of nimotuzumab combined with current chemoradiotherapy is effective for advanced stage head and neck tumor,and the side-effect was mild and acceptable.There are high clinical application values.
出处
《新疆医科大学学报》
CAS
2012年第3期293-296,共4页
Journal of Xinjiang Medical University
基金
国家自然科学基金资助项目(编号
30960432
81160327)
新疆维吾尔自治区科技支疆项目(编号
200991137)
新疆维吾尔自治区国际合作项目(编号:201141138)
新疆维吾尔自治区自然基金项目(编号:2009211B09)
乌鲁木齐市人才工程重点培养对象专项基金资助项目(编号:P112310001)
